Stryker has announced an adjustment to its commercial organizational structure. Spencer S. Stiles will serve as Group President of Orthopaedics and Spine and will oversee Stryker’s Joint Replacement, Trauma & Extremities and Spine divisions. J. Andrew Pierce, Group President of MedSurg and Neurotechnology will oversee Stryker’s Instruments, Medical, Endoscopy, Sustainability and Neurotechnology businesses.
Mr. Stiles and Mr. Pierce have both served at Stryker for over 20 years and will continue to report to Timothy J. Scannell, President and Chief Operating Officer in their newly expanded roles. Since August of 2018, Mr. Scannell has been responsible for all of the company’s commercial businesses and regions. This change will further accelerate the globalization and collaboration opportunities being unlocked in this structure and leverage the diverse experience of these leaders.
Stuart F. Simpson, President of Joint Replacement has left the company to pursue other career interests.
Source: Stryker
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.